Design Therapeutics, Inc. DSGN
9.84 USD -0.08 (-0.81%)
Regular-session close
9.84 0.00 0.00%
After hours · Nov 17, 4:33 PM ET
9.54 Day range 10.24
7.34 52-week range 15.94
- YTD
- +4.90%
- 1 year
- +32.44%
News
benzinga.com RBC Capital Maintains Outperform on Design Therapeutics, Lowers Price Target to $19 RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and lowers the price target from $20 to $19.
benzinga.com Design Therapeutics Q3 EPS $(0.32) Beats $(0.35) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.35) by 8.57 percent. This is a 6.67 percent decrease over losses of…
globenewswire.com Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 Cash and securities of $208.6 million at quarter-end provide strong financial runway…
seekingalpha.com Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the root cause of Friedreich Ataxia [FA]. The company's 4-week phase 1/2 RESTORE-FA data showed strong…
defenseworld.net Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat…
defenseworld.net Bank of New York Mellon Corp Purchases New Stake in Design Therapeutics, Inc. $DSGN Bank of New York Mellon Corp acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ: DSGN) in the undefined quarter, according to its most recent Form 13F filing with the Securities…
globenewswire.com Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,…
defenseworld.net BlackRock Inc. Takes Position in Design Therapeutics, Inc. $DSGN BlackRock Inc. acquired a new position in Design Therapeutics, Inc. (NASDAQ: DSGN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and…
247wallst.com Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different…
globenewswire.com Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending…
globenewswire.com Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design…
seekingalpha.com Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA.…
globenewswire.com Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,…
benzinga.com Design Therapeutics Stock Wobbles After Rare Genetic Disease Data Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
seekingalpha.com Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
globenewswire.com Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing
globenewswire.com Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026 CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,…
zacks.com Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
seekingalpha.com Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
globenewswire.com Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and…
globenewswire.com Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026
